Get the Stockscreener App
0.7372
1.79%
-0.0134
Cue Biopharma Inc stock is traded at $0.7372, with a volume of 211.02K.
It is down -1.79% in the last 24 hours and up +9.64% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.7506
Open:
$0.75
24h Volume:
211.02K
Relative Volume:
0.69
Market Cap:
$55.55M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.8101
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-16.50%
1M Performance:
+9.64%
6M Performance:
-49.16%
1Y Performance:
-4.89%
1-Day Range:
$0.7064
$0.7899
1-Week Range:
$0.7064
$0.9042
52-Week Range:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7372 | 56.56M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
How sentiment analysis helps forecast Cue Biopharma Inc.Free Breakout Confirmation With Entry Tracker - Newser
Will Cue Biopharma Inc. stock benefit from interest rate changesRisk Adjusted Trade Signal Screening Tool - Newser
Using data models to predict Cue Biopharma Inc. stock movement7-Day Equity Return Range Forecast Model - Newser
Why Cue Biopharma Inc. stock attracts strong analyst attentionLow Risk Strategy with Smart Entry Zones - Newser
Why is Cue Biopharma Inc. stock attracting strong analyst attentionBeginner Investor Data Feed With High Returns - jammulinksnews.com
Cue Biopharma Inc. stock trend outlook and recovery pathFree Market Momentum and Signal Alerts - Newser
Advanced analytics toolkit walkthrough for Cue Biopharma Inc.Fundamental Analysis for Value Stock Selection - Newser
Cue Biopharma Inc. Stock Support and Resistance Levels You Should KnowFree Trend Analysis for Safer Trades - Newser
What are the technical indicators suggesting about Cue Biopharma Inc.Market Forecast Report For Fast Growth - jammulinksnews.com
What are Cue Biopharma Inc. company’s key revenue driversPost Market Review For 2025 - jammulinksnews.com
Buy Signal for Cue Biopharma Inc. Stock Key Technical Indicators to WatchCapital Safe Picks with Consistent Gains - Newser
Earnings visualization tools for Cue Biopharma Inc.Free Momentum Based Equity Trading Plan - Newser
What technical models suggest about Cue Biopharma Inc.’s comebackFree Investment Strategy With Predictable Gains - Newser
What makes Cue Biopharma Inc. stock price move sharplyWeekly Price Target Forecast and Alerts - Newser
Published on: 2025-07-30 22:07:35 - Newser
Published on: 2025-07-30 23:27:11 - beatles.ru
Intrinsic Value of Cue Biopharma Inc. Stock: Is It Undervalued or OvervaluedFree Triple Digit Return Stock Predictions - Newser
Tools to monitor Cue Biopharma Inc. recovery probabilityFree Conservative Long Term Growth Plans - Newser
How Cue Biopharma Inc. stock performs during market volatilityFree Optimized Watchlist With Daily Adjustments - Newser
Cue Biopharma Inc. Outperforms Peers on Volume MetricsStock Screener With Smart Filters Highlights Top Picks - metal.it
Cue Biopharma Inc. Hits Oversold Level on RSI IndicatorHigh Return Stock Focus With Safety Emphasized - metal.it
Why Cue Biopharma Inc. stock is on top investor watchlistsWeekly Stock Picks with Trend Confidence - Newser
Can machine learning forecast Cue Biopharma Inc. recoveryFree Weekly Setup With 3x Return Potential - Newser
How did CUE's Q4 earnings surprise impact investor confidence? - AInvest
Published on: 2025-07-28 23:49:57 - metal.it
Cue Biopharma Inc. Flashes Buy Signal on Multi Timeframe ChartCommunity Strategy With High Win Rate Backtested - metal.it
What are analysts’ price targets for Cue Biopharma Inc. in the next 12 monthsExplosive market performance - jammulinksnews.com
What are the latest earnings results for Cue Biopharma Inc.Stay ahead with advanced stock screening tools - jammulinksnews.com
How does Cue Biopharma Inc. compare to its industry peersUnlock expert trading strategies for growth - jammulinksnews.com
Using AI based signals to follow Cue Biopharma Inc.Weekly Signal Report with Trend Summary - Newser
What catalysts could drive Cue Biopharma Inc. stock higher in 2025Breakthrough capital growth - jammulinksnews.com
Is Cue Biopharma Inc. stock overvalued or undervaluedGet high-impact stock recommendations now - jammulinksnews.com
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):